2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Women’s Health, Workforce, Adverse Events, Biological Processes, Apoptosis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3750 Predictors of response among patients treated with asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (ALERT CML)

Michael Mauro, MD, Ehab Atallah, MD2, Lisa Rein3, Jay Yang, MD4, Srinivas Tantravahi, MD5, James Thompson, M.D., M.S.6, Arielle Baim7, Sonia Maldonado-Schmidt8, Yan Gao9, Vamsi Kota, MD10, Omer Jamy, MD11, Anthony Michael Hunter, MD12, Jerald Radich, MD13, Jorge Cortes, MD14
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Karmanos Cancer Institute, Detroit, Michigan, United States
5 Huntsman Cancer Institute, Salt Lake City, Utah, United States
6 Roswell Park Cancer Institute, Buffalo, New York, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 Georgia Cancer Center, Augusta, Georgia, United States
11 University of Alabama at Birmingham, Birmingham, Alabama, United States
12 Emory Winship Cancer Institute, Atlanta, Georgia, United States
13 Fred Hutchinson Cancer Research, Seattle, Washington, United States
14 University of Alabama at Birmingham, Birmingham, Alabama, United States

Introduction: Asciminib, a first in class allosteric tyrosine kinase inhibitor (TKI), has demonstrated significant clinical efficacy among patients (pts) with chronic myeloid leukemia (CML) in chronic phase as initial therapy or after failure of prior TKIs. Several studies have reported rates of major molecular response (MMR) at 12 mo of 53% to 77% with asciminib as initial therapy, which is higher than rates reported with 1st or 2nd generation TKIs in historical and randomized cohorts; 24% to 49% have achieved MR4 at 12 mo with asciminib in these studies. We analyzed the factors predictive of achieving MR4 at 12 mo in the ALERT CML trial.

Methods: This is an ongoing, multicenter phase 2, investigator-initiated, single-arm, open-label study (NCT05143840) within the H Jean Khoury Cure CML Consortium (HJKC3) in the US. Patients received oral asciminib 40 mg twice daily or 80 mg once daily. The primary endpoint is the rate of MR4 or better at 12 mo. Patients who did not achieve MR4.5 after 24 mo on asciminib, experienced treatment failure at any time or had a warning response after 12 mo on asciminib were offered the addition of low-dose ATP-competitive TKI (lowTKI; imatinib 300 mg, dasatinib 50 mg or nilotinib 300 mg daily). The study is fully enrolled with 100 subjects. Odds of MR 4 or better at the 12-month timepoint were modeled using logistic regression.

Results: Between April 2022 to July 2026, 100 pts were enrolled in ALERT CML. With a median follow-up of 13.8 mo (range 0-50.8 mo), and a median exposure of 13.3 mo (range, 0-37.9), 85 pts (78 on asciminib, 7 on asciminib+lowTKI) remain on study treatment. At data cut off, low TKI was added to asciminib in 10 patients, of whom 7 remain on treatment (2 on FU, and 1 off study). Median time to start of lowTKI was 16.3 mo (range,12.3 -26.5 mo). Forty-eight pts have at least 12 mo of follow-up from asciminib inititation and have results for 12-month PCR and are included in this analysis. The median age for the evaluable pts was 51.5 yrs (range, 25-79 yrs), 67% are male. Sokal score was low in 17 (47%), intermediate in 15 (42%), high in 4 (11%) and missing in 12 (25%). Five of 39 (13%) pts with available NGS had detectable additional genomic abnormalities. Within the first 12 mo, 25 pts (52%) had a dose change, interruption or discontinuation. At 12 mo, 36/48 (75%) pts had achieved an MMR, including 20 (42%) who achieved MR4 or better, and 13 (27%) achieved MR4.5. Sokal risk score was the only factor associated with response. Among responders (n=20), Sokal was low, intermediate, and high in 71%, 29%, and 0%, respectively, compared with 32%, 50% and 18% of non-responders (n=28; p=0.014). In univariate logistic regression Sokal risk score was the only significant predictor of response MR4 or better at 12-mo at the p < 0.05 level, where higher risk was associated with worse odds of deep response. There was no difference in age, sex, WBC at diagnosis, platelets at diagnosis, NGS result (≥1 variant detected vs no variants), and any dose change (dose reduction, interruption or discontinuation vs none) within 12-mo between pts who did (n=20) or did not (n=28) achieve MR4 or better.

Conclusion: Asciminib as initial therapy for pts with CML in CP induced MR4 or better in 42% of pts at 12 mo. Pts with low Sokal risk have the best odds of achieving this response; the small number of high-risk patients warrants confirmation with additional follow-up. The lack of association between baseline genomic abnormalities and MR4 achievement is limited by the small number of evaluable patients at the time of this cutoff. These findings may help identify patients most likely to achieve early molecular milestones associated with future TFR readiness and can be further refined with ongoing follow-up and expanded enrollment maturity. With the study fully enrolled, additional follow-up will be available to expand on this analysis that may help identify pts most likely to achieve the response of interest in the ALERT CML study.

Michael Mauro, MD: Terns - Research Funding; Enliven - Research Funding; Novartis - Research Funding; Xspray - Consultancy (Includes expert testimony); Terns - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Xspray - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Enliven - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)